Informations générales (source: ClinicalTrials.gov)
Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)
Interventional
N/A
CHU de Reims (Voir sur ClinicalTrials)
mai 2018
novembre 2022
19 octobre 2024
Small intestine carcinoid tumors are rare. Small intestine Familial Carcinoid Tumors
(FCT) are defined by the occurrence of at least 2 cases of this tumor type in first- or
second-degree relatives. The estimated prevalence of FCT is 2.6%-3.7% in patients with
small intestine carcinoid tumors. Because of its rarity, epidemiologic, clinic and
pathologic features of FCT have been scarcely described. Molecular abnormalities
associated with FCT have been poorly explored. Constitutional genetic factors
predisposing to FCT have not been discovered to date. Only one abnormality (mutation of
the IPMK gene) has been reported in one FCT family only, but not found in other series.
The main objective of this study is to identify the constitutional factors predisposing
to small-intestine FCT (and other midgut localizations: ascending colon and appendix).
The secondary objectives are to describe the clinic and pathologic features associated
with FCT.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 04/09/2024 13:49:46 | Contact (sur clinicalTrials) | |||
| CLCC RENE HUGUENIN INSTITUT CURIE | 07/08/2024 08:21:58 | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Damien JOLLY - Reims - France | Guillaume CADIOT | Contact (sur clinicalTrials) | |||
Critères
Tous
inclusion criteria :
- Small-intestine (or ascending colon or appendix) neuroendocrine tumor (proven
histologically)
- At least one first- or second-degree relative with a small-intestine (or ascending
colon or appendix) neuroendocrine tumor (proven histologically)
- Agreement to participate to the study exclusion criteria :
- Subjects unable to provide consent
- Small-intestine (or ascending colon or appendix) neuroendocrine tumor (proven
histologically)
- At least one first- or second-degree relative with a small-intestine (or ascending
colon or appendix) neuroendocrine tumor (proven histologically)
- Agreement to participate to the study exclusion criteria :
- Subjects unable to provide consent